SHANK2 and breast cancer: SHANK2 has not been well studied in BC, but was shown to induce drug resistance in advanced oropharyngeal carcinomas54, and high levels of MAD1L1 expression correlate with reduced tumour cell sensitivity to chemotherapy55.